TSX:ONC 0.70 CAD +0.03 +4.48% Volume: 235,989 August 27, 2015
NASDAQ:ONCY 0.53 USD +0.01 +2% Volume: 493,847 August 27, 2015


REOLYSIN® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus, which is widely found in the environment. By adulthood, most people have been exposed to the reovirus. The reovirus is non-pathogenic, which means that infections are typically asymptomatic. In clinical trials, REOLYSIN® has been shown to be well-tolerated, with patients exhibiting only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with chemotherapy and radiotherapy for various cancers, including head and neck cancers in an ongoing Phase III clinical trial.

REOLYSIN® is based upon research conducted by the Chief Operating Officer of Oncolytics, Dr. Matt Coffey. It was found that the reovirus was able to infect and selectively destroy cancer cells. When a normal cell is infected with the reovirus, an antiviral response is activated, which prevents the virus from replicating within the cell. However, inside a cancer cell with one or more mutations on a growth pathway called the Ras pathway, there is an aberrant antiviral response that is unable to prevent the virus from replicating. This abnormality allows the reovirus to multiply to an extent that is fatal to the cancer cell.

Click here to view Oncolytics' latest REOLYSIN® video


Clinical Trials

Find out about our clinical trial program for REOLYSIN®.

Learn More

Latest News

August 27, 2015 Oncolytics Biotech® Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer
August 26, 2015 Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung Cancer Study
August 12, 2015 MEDIA ADVISORY - Oncolytics Biotech® Inc. to Participate in the 35th Annual Canaccord Genuity Growth Conference
Sign up to receive e-mail updates *